Subscribe or Manage Preferences

Self-Reports of 6-Mercaptopurine Intake in Childhood Acute Lymphoblastic Leukemia Unreliable

Electronic reporting more accurate than self-reporting
Web Exclusives: Value-Based Care - May 2016 - Hematologic Cancers
Phoebe Starr

Approximately 40% of children with acute lymphoblastic leukemia (ALL) fail to take 6-mercaptopurine (6-MP) as prescribed, and a sizable majority of parents and children with ALL overreport the intake of a critical drug for maintaining remission, according to a study reported by lead investigator Wendy Landier, PhD, RN, NP, Children’s of Alabama, Birmingham, and colleagues at ASH 2015. The study suggests that electronic reporting using TrackCap, a medication event monitoring system (MEMS), is more reliable than self-reports.

Approximately 88% of parents of children with ALL and children with ALL aged >12 years overreported the number of days 6-MP was taken, and 24% overreported by ≥5 days monthly in >50% of the study months.

“Subjective overreporting of 6-MP adherence during maintenance therapy is common for children with ALL, particularly in nonadherent patients, and should be viewed with caution,” said Dr Landier.

She explained that approximately 2 years of maintenance chemotherapy that includes daily oral 6-MP are needed to achieve durable remission in childhood ALL. The team previously showed that adherence rates of <95% are associated with a 3.7 times higher risk for relapse.

The Children’s Oncology Group AALL03N1 study was a prospective study designed to compare self-reported 6-MP intake (by parents of children aged <12 years and by patients aged ≥12 years) versus electronic monitoring using TrackCap, a MEMS electronic system that records each opening of the medication bottle. At the end of each of the 4 study months, the 6-MP intake according to self-reports and to electronic monitoring were compared. The study analyzed a total of 1344 patient-months of self-reports and MEMS data.

The study enrolled 416 patients with a median age of 6 years. Of these patients, 38% had high-risk disease according to National Cancer Institute criteria, and 40.4% were found to be nonadherent. A total of 66% of the patients in the study were male, and 61% were from families with paternal education less than college.

Overall, 12% of the patients were “perfect reporters,” 24% were overreporters by ≥5 days monthly in ≥2 of the 4 months, <1% underreported, and 64% of the patients were categorized as other.

At the end of each month, a significant difference was found between the self-reporting and electronic reporting groups (P <.001). At all time points, the median number of self-reports was higher than that for MEMS.

A multivariate analysis identified 4 factors associated with overreporting—age >12 years, nonwhite race, paternal education less than college, and nonadherence.

For each increasing year of the child’s age, the risk for overreporting increased by 7%. The children’s self-reports were more likely to overestimate 6-MP intake than the parents’ reporting.

Furthermore, nonadherent patients were much more likely to be overreporters, with 2% of perfect reporters being nonadherent and >80% of overreporters being nonadherent.

Dr Landier and colleagues plan to develop future interventions to educate parents and children with ALL about the importance of adherence.

Related Items
Imatinib Can Be Safely Discontinued in Patients with Deep Molecular Response
Chase Doyle
Web Exclusives: Value-Based Care - May 2016 published on May 9, 2016 in Hematologic Cancers
Last modified: May 9, 2016
  • Rheumatology Practice Management
  • Lynx CME
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology